Lite Strategy CEO‑CFO Justin J. Buys Big on a $1.03 Floor, Betting on a Cancer‑Therapy Upswing
Lite Strategy insiders buy 455,000 shares at $0 each, showing confidence in the company’s cancer‑metabolism pipeline amid volatile stock price.
3 minutes to read